Background: Pelvic pain around the time of mensturation without
any identifiable pathologic lesion present from menarche is called primary
dysmenorrhea. The pain is believed to be related to prostaglandin (PG). Women
with dysmenorrhoea have a relatively high concentration of PGF 2 alpha in
menstrual fluid and suppression of PG synthesis has become the main treatment.
Aim: To compare mean reduction in pain in patients
presenting with primary dysmenorrhea given vitamin E & Mefenamic acid
versus Mefenamic acid alone.
Results: It was a randomized
controlled trial which was conducted in Department
of Obstetrics & Gynecology, THQ Raiwind Hospital, Lahore for 6 months duration
w.e.f 01/02/2017 to 31/07/2017. In this study, 18(36%) in Vitamin-E group and 21(42%)
in Mefenamic acid group were between 15-20 years while 32(64%) in Vitamin-E
group and 29(58%) in Mefenamic acid group were between 21-25 years, mean±sd was calculated as 20.86±2.92 and 20.66±2.86 years respectively, mean dysmenorrheal pain at baseline was
recorded as 50.06±10.27 in Vitamin-E
group and 50.14±10.28 in Mefenamic
acid group, p value < 0.754, showing that both groups are insignificant,
mean dysmenorrheal pain after treatment was recorded as 20.50±10.04 in Vitamin-E group and 30.22±10.28 in Mefenamic acid group, p value was < 0.002 showing significant difference
between the two group, comparison of mean reduction in dysmenorrheal pain after
treatment was recorded as 20.56±0.91 in Vitamin-E group and 10.92±0.75 in Mefenamic acid group, p value was < 0.000, showing significant difference.
Conclusion: We concluded that there is a significant mean reduction in dysmenorrhic
pain in patients given Mefenamic Acid + Vitamen E as compared to patients given
Mefenamic Acid alone.
Keywords: Dysmenorrhic pain, Mefenamic Acid + Vitamen
E, mean reduction in dysmenorrhic pain